NervGen Pharma Corp.
NGEN.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.07% | 68.91% | 35.78% | -2.38% | 7.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.44% | 6.63% | 14.09% | 35.69% | 108.05% |
| Operating Income | 15.44% | -6.63% | -14.09% | -35.69% | -108.05% |
| Income Before Tax | 22.29% | -15.05% | -58.14% | 2.81% | -21.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.29% | -15.05% | -58.14% | 2.81% | -21.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.29% | -15.05% | -58.14% | 2.81% | -21.04% |
| EBIT | 15.44% | -6.63% | -14.09% | -35.69% | -108.05% |
| EBITDA | 15.46% | -6.66% | -14.71% | -35.83% | -109.88% |
| EPS Basic | 25.63% | -11.74% | -34.60% | 17.23% | -2.59% |
| Normalized Basic EPS | 25.43% | -11.94% | -34.25% | 17.32% | -2.67% |
| EPS Diluted | 25.63% | -11.74% | -34.60% | 17.23% | -2.59% |
| Normalized Diluted EPS | 25.43% | -11.94% | -34.25% | 17.32% | -2.67% |
| Average Basic Shares Outstanding | 4.41% | 2.87% | 17.37% | 17.50% | 17.93% |
| Average Diluted Shares Outstanding | 4.41% | 2.87% | 17.37% | 17.50% | 17.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |